pharma news today glp-1 obesity drugs today Dozens of new are coming: these are the ones to watch Pfizer moves forward with weight-loss

for example, hawthorn leaf flavonoids have been shown to exert neuroprotective effects in an AD model by activating the Nrf2/ARE pathway, enhancing antioxidant enzyme activities, and reducing oxidative stress and neuroinflammation (Xu et al., 2023)

Heffernan et al., The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and 3-AR Knock-Out Mice, Endocrinology, vol

Pfizer halted development of its oral GLP-1 danuglipron in 2025 after a trial participant developed liver injury, reflecting safety concerns that require ongoing monitoring with real-world data

10.2337/db08-1158 66

Curristin, S

It also contains Niacinamide that decreases hyperpigmentation and protects skin barrier